CORDIS
EU research results

CORDIS

English EN
Integrated IMMUnoprofiling of large adaptive CANcer patients cohorts

Integrated IMMUnoprofiling of large adaptive CANcer patients cohorts

Objective

IMMUcan proposes an inclusive and integrated European immuno-oncology platform. IMMUcan will access high-quality human biological material (tissue, blood, stool and saliva) and clinical data from patients with colorectal, lung, head & neck, breast, gastric cancers and immune checkpoints inhibitors failures. We have assembled a strong consortium with ten expert clinical centers, access to large volumes of the required tumor types. IMMUcan will mobilize the majority of academic trials running or expected to start recruiting patients during the project period. A centralized workflow for samples, via a state-of-the-art biobank will increase reproducibility as all tissues will be processed and stored in a uniform way, following proofed SOPs. The project will perform in depth immunoprofiling with cutting edge technologies including CyTOFF, single cell RNA-seq, peptidogenomics or microbiome analysis. IMMUcan will analyze the data in order to understand the host/tumour interaction in the absence of treatment (naïve population) and with treatment (patients in follow-up) to identify potential predictive biomarker for response to immunotherapy, or develop rationale for combination therapies. IMMUcan will provide an IT platform and legal/ethical contractual framework where participants from both academia and industry can pursue their own independent investigations utilizing the IMMUcan data and effectively testing and improving the functioning and relevance of the database. A sustainability plan will be developed to ensure the collection of follow-up data and the accessibility of the data platform. The use of the data generating throughout this project, for future research, will be supported.

Coordinator

EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL

Address

Avenue E. Mounier 83
1200 Brussels

Belgium

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 7 246 773,75

Participants (27)

Sort alphabetically

Sort by EU Contribution

Expand all

SIB INSTITUT SUISSE DE BIOINFORMATIQUE

Switzerland

EU Contribution

€ 1 323 000

CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS

Switzerland

EU Contribution

€ 1 460 332,90

LUXEMBOURG INSTITUTE OF HEALTH

Luxembourg

EU Contribution

€ 2 749 727,35

FORUM EUROPEEN DES PATIENTS (FPE)

Luxembourg

EU Contribution

€ 250 000

KATHOLIEKE UNIVERSITEIT LEUVEN

Belgium

EU Contribution

€ 1 712 880

KING'S COLLEGE LONDON

United Kingdom

EU Contribution

€ 765 066

LIGUE NATIONALE CONTRE LE CANCER

France

EU Contribution

€ 120 000

INSTITUT JULES BORDET

Belgium

EU Contribution

€ 20 000

THE UNIVERSITY OF BIRMINGHAM

United Kingdom

EU Contribution

€ 160 000

INSTITUT CURIE

France

EU Contribution

€ 410 000

CENTRE ANTICANCEREUX LEON BERARD

France

EU Contribution

€ 100 000

UNIVERSITAT ZURICH

Switzerland

EU Contribution

€ 573 700

DE DUVE INSTITUTE

Belgium

CHARITE - UNIVERSITAETSMEDIZIN BERLIN

Germany

EU Contribution

€ 20 000

FUNDACIO CENTRE DE REGULACIO GENOMICA

Spain

EU Contribution

€ 190 200

OWKIN FRANCE

France

WEIZMANN INSTITUTE OF SCIENCE

Israel

EU Contribution

€ 100 000

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

EU Contribution

€ 628 320

MERCK KOMMANDITGESELLSCHAFT AUF AKTIEN

Germany

ABBVIE INC

United States

Bayer

Germany

Eli Lilly and Company Limited

United Kingdom

GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD.

United Kingdom

JANSSEN PHARMACEUTICA NV

Belgium

SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT

France

INSTITUT DE RECHERCHES INTERNATIONALES SERVIER

France

INSTITUT DE RECHERCHE PIERRE FABRESAS

France

Project information

Grant agreement ID: 821558

Status

Ongoing project

  • Start date

    1 March 2019

  • End date

    31 August 2024

Funded under:

H2020-EU.3.1.7.

  • Overall budget:

    € 34 937 500

  • EU contribution

    € 17 830 000

Coordinated by:

EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL

Belgium